Home > Healthcare > Pharmaceuticals > Finished Drug Form > DNA Repair Drugs Market

DNA Repair Drugs Market Share

Report ID: GMI10274
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

DNA Repair Drugs Market Share

The competitive landscape in the market is characterized by intense research and development activities aimed at addressing various aspects of DNA repair mechanisms to combat diseases like cancer. Key players are actively engaged in developing novel therapies that target specific DNA repair pathways implicated in cancer progression and resistance to treatment. Additionally, partnerships and collaborations between pharmaceutical firms, academic institutions, and biotechnology companies are driving innovation and accelerating the clinical development of DNA repair drugs. The market is poised for growth as these therapies hold promise for personalized medicine approaches, offering potential benefits across a spectrum of oncological indications.

DNA Repair Drugs Market Companies

Prominent players operating in the DNA repair drugs industry include:

AstraZeneca Plc
AbbVie
Artios Pharma Limited
Breakpoint Therapeutics
ClovisOncology Inc.
FoRx Therapeutics
GlaxoSmithKline plc.
Johnson & Johnson
Luciole Pharmaceuticals
Merck KGaA
Onxeo
Pfizer Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

DNA repair drugs market was valued at USD 6.8 billion in 2023 and is set to register growth at 8.9% CAGR during 2024-2032 driven by the increasing prevalence of cancer worldwide.

The ovarian cancer segment in the market held 38.4% share in 2023 owing to the increasing prevalence of ovarian cancer worldwide.

North America DNA repair drugs market generated USD 2.6 billion in 2023 and is anticipated to reach USD 5.5 billion by 2032 attributed to robust R&D activities, and the presence of leading pharmaceutical and biotechnology companies.

AstraZeneca Plc, AbbVie, Artios Pharma Limited, Breakpoint Therapeutics, ClovisOncology Inc., FoRx Therapeutics, GlaxoSmithKline plc., Johnson & Johnson, Luciole Pharmaceuticals, and Merck KGaA among others.